Neurorubine (Thiamine Hydrochloride, Cyanocobalamin, Pyridoxine Hydrochloride)

Thiamine hydrochloride acts as a cofactor for enzymes involved in carbohydrate metabolism, such as pyruvate dehydrogenase, facilitating conversion of glucose to energy and supporting neuronal health. In combination with pyridoxine and cyanocobalamin, it helps maintain normal nerve conduction and red blood cell formation.

The specific dose of Neurorubine is determined by the prescribing clinician based on the patient’s clinical condition, vitamin status and route of administration. Healthcare professionals should follow local guidelines and individual patient needs when selecting a regimen.

Safety data for Neurorubine in pregnancy and lactation are limited. Clinicians should evaluate the potential benefits against any unknown risks and consider alternative therapies when appropriate. Consultation with a maternal‑fetal medicine specialist is recommended.

To request Neurorubine, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Neurorubine combines three essential B‑vitamins in a single injectable formulation, offering rapid systemic availability compared with oral supplements. This can be advantageous in patients with malabsorption, severe deficiency or when a quick therapeutic effect is required, whereas oral products may be preferred for long‑term maintenance.

Neurorubine should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures to maintain stability and potency.

Neurorubine is administered by a qualified healthcare professional via intravenous, intraarticular or periarticular injection, depending on the therapeutic indication and clinical setting. Proper aseptic technique and appropriate dilution (if required) should be followed according to institutional protocols.

Serious risks include anaphylactic reactions, severe hypotension, acute hemolysis in patients with G6PD deficiency, and rare thromboembolic events. Immediate medical attention is required if any signs of severe hypersensitivity or cardiovascular instability occur.

Neurorubine is contraindicated in individuals with known hypersensitivity to any of its B‑vitamin components. Caution is advised for patients with severe renal impairment, G6PD deficiency, or a history of severe allergic reactions to injectable vitamins.